EC approves Revlimid for mantle cell lymphoma
Celgene’s Revlimid (lenalidomide) has been approved by the European Commission (EC) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Click on this link for more information.
